Strain identifier

BacDive ID: 1584

Type strain: No

Species: Sphaerophorus intermedius

Strain Designation: LRA 048 07 85

Strain history: CIP <- 1993, R. Mercier, bioMérieux, La Balme-les-Grottes, France: strain LRA 048 07 85 <- 1985, Analytab, Plainview, USA <- 1968, T. Bergan, Oslo, Norway, Sphaerophorus intermedius

NCBI tax ID(s): 817 (species)

« Browse strain by BacDive ID »

expand / minimize allblue arrow down

Exclude non-curated data/information

Sphaerophorus intermedius LRA 048 07 85 is an anaerobe, mesophilic, Gram-negative human pathogen that was isolated from pleural fluid.

  1. Gram-negative
  2. rod-shaped
  3. anaerobe
  4. human pathogen
  5. mesophilic
  6. 16S sequence
  7. Bacteria
  • Availability in culture collections External linksarrow_down
  • [Ref.: #762] Culture collection no. CCUG 25931, DSM 1396, ATCC 23745, NCTC 10581, CIP 103754, JCM 11018
    [Ref.: #71229] *
    Literature: Only first 10 entries are displayed. Click here to see all.Click here to see only first 10 entries.
    Topicarrow to sort Titlearrow to sort Authorsarrow to sort Journalarrow to sort DOIarrow to sort Yeararrow to sort
    Pathogenicity Effect of oligosaccharides on the adhesion of gut bacteria to human HT-29 cells. Altamimi M, Abdelhay O, Rastall RA Anaerobe 10.1016/j.anaerobe.2016.03.010 2016 *
    Pathogenicity Effect of dosing and dosing frequency on the efficacy of ceftizoxime and the emergence of ceftizoxime resistance during the early development of murine abscesses caused by Bacteroides fragilis and Enterobacter cloacae mixed infection. Stearne LE, Goessens WH, Mouton JW, Gyssens IC Antimicrob Agents Chemother 10.1128/AAC.01486-06 2007 *
    Metabolism Effect of recombinant murine granulocyte colony-stimulating factor with or without fluoroquinolone therapy on mixed-infection abscesses in mice. Stearne LE, Vonk AG, Kullberg BJ, Gyssens IC Antimicrob Agents Chemother 10.1128/AAC.49.9.3668-3675.2005 2005 *
    Pathogenicity Pharmacodynamics of trovafloxacin and levofloxacin against Bacteroides fragilis in an in vitro pharmacodynamic model. Peterson ML, Hovde LB, Wright DH, Brown GH, Hoang AD, Rotschafer JC Antimicrob Agents Chemother 10.1128/AAC.46.1.203-210.2002 2002 *
    Genetics Use of rep-PCR to define genetic relatedness among Bacteroides fragilis strains. Moraes SR, Goncalves RB, Mouton C, Seldin L, Ferreira MCS, Domingues RMCP J Med Microbiol 10.1099/0022-1317-49-3-279 2000 *
    Pathogenicity Fluoroquinolone resistance in Bacteroides fragilis following sparfloxacin exposure. Peterson ML, Hovde LB, Wright DH, Hoang AD, Raddatz JK, Boysen PJ, Rotschafer JC Antimicrob Agents Chemother 10.1128/AAC.43.9.2251 1999 *
    Phylogeny Bacteroides fragilis isolates compared by AP-PCR. Moraes SR, Goncalves RB, Mouton C, Seldin L, Ferreira MC, Domingues RM Res Microbiol 10.1016/s0923-2508(99)80050-3 1999 *
    Genetics Structural elucidation of the capsular polysaccharide of Bacteroides fragilis strain 23745M1. Pavliak V, Uhrin D, Brisson JR, Tzianabos AO, Kasper DL, Jennings HJ Carbohydr Res 10.1016/0008-6215(95)00158-p 1995 *
    Enzymology Evaluation of activity of temafloxacin against Bacteroides fragilis by an in vitro pharmacodynamic system. Zabinski RA, Vance-Bryan K, Krinke AJ, Walker KJ, Moody JA, Rotschafer JC Antimicrob Agents Chemother 10.1128/AAC.37.11.2454 1993 *
    Phylogeny Surface structures, haemagglutination and cell surface hydrophobicity of Bacteroides fragilis strains. Oyston PC, Handley PS J Gen Microbiol 10.1099/00221287-136-5-941 1990 *

Change proposal

You found an error in BacDive? Please tell us about it!

Note that changes will be reviewed and judged. If your changes are legitimate, changes will occur within the next BacDive update. Only proposed changes supported by the according reference will be reviewed. The BacDive team reserves the right to reject proposed changes.

Field you want to change:


CAPTCHAReload captcha

Change proposal

Successfully sent